TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27037432

Group type: EXPERIMENTAL
Intervention: Ultrasound guided corticosteroid injection (40 mg triamcinolone acetonide and 2 ml 1% lignocaine)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-ultrasound guided corticosteroid injection (40 mg triamcinolone acetonide and 2 ml 1% lignocaine)
Number of subjects: 36
Study: 25158081

Group type: EXPERIMENTAL
Intervention: NRT patches (15 mg per 16 hours) for 8 weeks
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: NRT patches
Number of subjects: 1050
Study: 22167121

Group type: EXPERIMENTAL
Intervention: Adherence intervention (asthma education, motivational interviewing, problem-solving skills training, 1 month cell-phone with tailored text messaging)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (asthma education; cell-phone without tailored messaging)
Number of subjects: 26
Study: 20346057

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (30 or 45 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19015469

Group type: EXPERIMENTAL
Intervention: Alvimopan, 12 mg, administered orally 30 to 90 minutes preoperatively and twice daily postoperatively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized accelerated postoperative care pathway alone (Placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alvimopan, 12 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16044840

Group type: EXPERIMENTAL
Intervention: Athenolol (50 mg daily) with antiatherogenic lactoovovegetarian diet
Number of subjects: 84

Group type: COMPARATOR
Intervention: Athenolol (50 mg daily) with standard antiatherogenic diet
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Hypotiazide (25 mg daily) with antiatherogenic lactoovovegetarian diet
Number of subjects: 84

Group type: COMPARATOR
Intervention: Hypotiazide (25 mg daily) with standard antiatherogenic diet
Number of subjects: 84
Study: 12444212

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 mg) and Amiloride (5 mg) combination
Number of subjects: 16

Group type: COMPARATOR
Intervention: Amiloride (5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chlorthalidone and Amiloride combination
Number of subjects: 16
Study: 9660361

Group type: EXPERIMENTAL
Intervention: Simultaneous initiation of indinavir, zidovudine, and lamivudine
Number of subjects: 97

Group type: COMPARATOR
Intervention: Sequential initiation of zidovudine and lamivudine
Number of subjects: 97

Group type: COMPARATOR
Intervention: Sequential initiation of indinavir
Number of subjects: 97
Study: 8620678

Group type: EXPERIMENTAL
Intervention: Zileuton 800mg administered twice daily from day 4 to day 8
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo administered twice daily from day 4 to day 8
Number of subjects: 14
Study: 2568519

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (6 g/day of n-3 fatty acids) for 6 months, starting 5.4 days before PTCA.
Number of subjects: 204

Group type: COMPARATOR
Intervention: Olive oil placebo (control group).
Number of subjects: 204
Study: 779756

Group type: EXPERIMENTAL
Intervention: Marijuana smoking (0.739 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo smoking (0.739 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No smoking control period
Number of subjects: 10
Study: 29023326

Group type: EXPERIMENTAL
Intervention: SS + ES
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: SS
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control
Number of subjects: 31
Study: 28682745

Group type: EXPERIMENTAL
Intervention: Community resource mapping intervention
Number of subjects: 11
Study: 25539730

Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 1502

Group type: COMPARATOR
Intervention: ABV (doxorubicin, bleomycin, and vinblastine)
Number of subjects: 1502

Group type: COMPARATOR
Intervention: AVD (doxorubicin, vinblastine, and dacarbazine)
Number of subjects: 1502

Group type: COMPARATOR
Intervention: AV (doxorubicin and vinblastine)
Number of subjects: 1502
Study: 23647307

Group type: EXPERIMENTAL
Intervention: IWT plus post-exercise macronutrient supplementation (7.6 g protein, 32.5 g carbohydrate, and 4.4 g fat)
Number of subjects: 35

Group type: COMPARATOR
Intervention: IWT alone (CNT)
Number of subjects: 35
Study: 21521915

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1% povidone iodine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2% sodium hypochlorite
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2.5% hydrogen peroxide followed by 2% sodium hypochlorite
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2% sodium hypochlorite alone
Number of subjects: 0
Study: 19210009

Group type: EXPERIMENTAL
Intervention: Cognitively based extension of the Healthy Start home visitation program (HV+)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Visitation condition without the cognitive component (HV)
Number of subjects: 102
Study: 17097995

Group type: EXPERIMENTAL
Intervention: Two bolus doses of daclizumab (1 mg/kg) on days 1 and 14 posttransplantation
Number of subjects: 81

Group type: COMPARATOR
Intervention: Five bolus doses of daclizumab (1 mg/kg) every 14 days
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Two bolus doses of daclizumab
Number of subjects: 81

Group type: COMPARATOR
Intervention: Five bolus doses of daclizumab
Number of subjects: 81
Study: 14746621

Group type: EXPERIMENTAL
Intervention: Rinse-off product containing methyldibromoglutaronitrile (MDBGN)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Rinse-off product without methyldibromoglutaronitrile (MDBGN)
Number of subjects: 28
Study: 11269572

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GJ)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 22
Study: 9230827

Group type: EXPERIMENTAL
Intervention: Focal photocoagulation
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Very severe hard exudates
Number of subjects: 109
Study: 8548226

Group type: EXPERIMENTAL
Intervention: rHuEPO (300 units/kg as first administration, and 100 units/kg 4, 8 and 12 days later) with supplemental iron
Number of subjects: 22

Group type: COMPARATOR
Intervention: Iron saccharate 200 mg/day intravenously for 12 consecutive days
Number of subjects: 22
Study: 2596436

Group type: EXPERIMENTAL
Intervention: Adequate diet (Zn-Cu ratio 2:1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-Zn diet (Zn-Cu ratio 15:1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-Cu diet (Zn-Cu ratio 5:1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Restricted Cu diet
Number of subjects: 15
Study: 65273

Group type: EXPERIMENTAL
Intervention: 0.7 mg/kg delta9‐tetrahydrocannabinol (THC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.0 ml/kg 95% ethanol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Set size
Number of subjects: 12
Study: 31834549

Group type: EXPERIMENTAL
Intervention: Differentially expressed circRNAs in Alzheimer's disease patients
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Top 10 upregulated and downregulated circRNAs
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Gene ontology and KEGG pathway analyses
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: circRNA‐miRNA‐mRNA network
Number of subjects: 5
Study: 30916412

Group type: EXPERIMENTAL
Intervention: Sodium benzoate (SB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate (SPB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27841942

Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 692
Study: 24385118

Group type: EXPERIMENTAL
Intervention: Topical cosmetic formulation containing N-acetyl tyrosinamide
Number of subjects: 70

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Topical cosmetic formulation
Number of subjects: 70
Study: 22755344

Group type: EXPERIMENTAL
Intervention: Back care education programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 20708904

Group type: EXPERIMENTAL
Intervention: Intramuscular levetiracetam (500mg, 5ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous levetiracetam
Number of subjects: 10
Study: 18368612

Group type: EXPERIMENTAL
Intervention: Agonist pharmacotherapy (specific agonists not detailed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indirect agonists (dexamphetamine and methylphenidate)
Number of subjects: 0
Study: 16299646

Group type: EXPERIMENTAL
Intervention: Ulinastatin 150,000 U per day for 5 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: 250 ml hydrochloric sodium before chemotherapy for 5 days (Control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ulinastatin treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 12577189

Group type: EXPERIMENTAL
Intervention: Pamidronate 30 mg intravenously every 3 months, combined with 1000 mg calcium and 1000 IU vitamin D per day.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Historical control group treated only with calcium and vitamin D.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pamidronate treatment.
Number of subjects: 34
Study: 10235519

Group type: COMPARATOR
Intervention: Standard pancreaticoduodenectomy
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Radical pancreaticoduodenectomy
Number of subjects: 114
Study: 7758556

Group type: EXPERIMENTAL
Intervention: Baclofen 25 mg before sleep
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2200894

Group type: EXPERIMENTAL
Intervention: 1988-1989 trivalent split-antigen influenza vaccine
Number of subjects: 336

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 336
Study: 367087

Group type: EXPERIMENTAL
Intervention: Quinidine Lipettes (sustained release preparation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other quinidine preparations on the Swedish market
Number of subjects: 0
Study: 31155604

Group type: EXPERIMENTAL
Intervention: PtCr-EES
Number of subjects: 3755

Group type: COMPARATOR
Intervention: CoCr-ZES
Number of subjects: 3755
Study: 28880935

Group type: EXPERIMENTAL
Intervention: 32-minute walking test (32MWT)
Number of subjects: 17
Study: 25830813

Group type: EXPERIMENTAL
Intervention: Test Cigarette-High Tar (TCH)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Test Cigarette-Low Tar (TCL)
Number of subjects: 20
Study: 23306361

Group type: EXPERIMENTAL
Intervention: Three injection techniques
Number of subjects: 0
Study: 20841317

Group type: EXPERIMENTAL
Intervention: Multidimensional programme combining physical training, patient transfer techniques, and stress management
Number of subjects: 306

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 306
Study: 19439456

Group type: EXPERIMENTAL
Intervention: Laparoscopic biliopancreatic diversion with duodenal switch
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laparoscopic Roux‐en‐Y gastric bypass
Number of subjects: 60
Study: 17287106

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 14977662

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11426559

Group type: EXPERIMENTAL
Intervention: Peripherally inserted central catheters (PICCs)
Number of subjects: 40
Study: 9386028

Group type: EXPERIMENTAL
Intervention: Midwives' unit
Number of subjects: 2844

Group type: COMPARATOR
Intervention: Consultant-led labour ward
Number of subjects: 2844
Study: 7970440

Group type: EXPERIMENTAL
Intervention: Adenosine infusion at 140 micrograms kg‐1 min‐1
Number of subjects: 90

Group type: COMPARATOR
Intervention: Adenosine infusion combined with low-level dynamic exercise
Number of subjects: 90
Study: 3675695

Group type: EXPERIMENTAL
Intervention: Amoxicillin + ambroxol 60 mg p.o.t.i.d.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Amoxicillin 1000 mg p.o.t.i.d.
Number of subjects: 14
Study: 29572284

Group type: EXPERIMENTAL
Intervention: IV aminophylline 250 mg
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 26903399

Group type: EXPERIMENTAL
Intervention: 0.625 mg/day of oral conjugated equine estrogen (CEE) for 3 months
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1.0 mg/day of oral 17β estradiol (E2) for 3 months
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 50 μg/day of transdermal 17βE2 for 3 months
Number of subjects: 45
Study: 25024243

Group type: EXPERIMENTAL
Intervention: Electronically delivered decision support tools
Number of subjects: 603409

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 603409
Study: 23877659

Group type: EXPERIMENTAL
Intervention: TroVax plus docetaxel
Number of subjects: 25

Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 25
Study: 21211205

Group type: EXPERIMENTAL
Intervention: Single intra-articular 25 mg etanercept injection
Number of subjects: 70

Group type: COMPARATOR
Intervention: 2 ml compound betamethasone
Number of subjects: 70
Study: 18831885

Group type: EXPERIMENTAL
Intervention: Forced air warming with a surgical access blanket
Number of subjects: 90

Group type: COMPARATOR
Intervention: Forced air warming combined with an upper body blanket
Number of subjects: 90

Group type: COMPARATOR
Intervention: Circulating water mattress
Number of subjects: 90
Study: 17245238

Group type: EXPERIMENTAL
Intervention: Intra-articular reconstruction (patellar tendon autograft)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Intra-articular reconstruction plus extra-articular quadricipital tendon plasty
Number of subjects: 63
Study: 14974908

Group type: EXPERIMENTAL
Intervention: 1 mg oestradiol and 0.5 mg norethisterone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 10801290

Group type: EXPERIMENTAL
Intervention: Lipid (1 kcal/min)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lipid (2 kcal/min)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lipid (3 kcal/min)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 9
Study: 8668567

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.2 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral hydroxyzine (3.7 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (nitrous oxide)
Number of subjects: 30
Study: 1601148

Group type: EXPERIMENTAL
Intervention: hCG administered when the mean diameter of the largest follicle reached 18 mm (Group 1, n = 79)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: hCG administered 1 day after criteria (Group 2, n = 84)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: hCG administered 2 days after criteria (Group 3, n = 84)
Number of subjects: 247
Study: 6318605

Group type: EXPERIMENTAL
Intervention: Fentanyl preloading (5 micrograms/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no fentanyl preloading, received 4 mg/kg of thiopental)
Number of subjects: 30
Study: 31201809

Group type: EXPERIMENTAL
Intervention: Uterosacral ligament suspension
Number of subjects: 374

Group type: COMPARATOR
Intervention: Sacrospinous ligament suspension
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Transvaginal native tissue repairs and midurethral sling
Number of subjects: 374
Study: 28840301

Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 45
Study: 26472349

Group type: EXPERIMENTAL
Intervention: Intervention group (utilisation of social networks for education)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0
Study: 25016216

Group type: EXPERIMENTAL
Intervention: Collaborative care treatment model for depression
Number of subjects: 168

Group type: COMPARATOR
Intervention: Public health Maternity Support Services (MSS)
Number of subjects: 168
Study: 22868976

Group type: EXPERIMENTAL
Intervention: Unplugged intervention (12 lessons delivered during the 2007-2008 academic year)
Number of subjects: 1753

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1753

Group type: EXPERIMENTAL
Intervention: Unplugged intervention
Number of subjects: 1753

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1753
Study: 18622656

Group type: EXPERIMENTAL
Intervention: TNF‐GIF‐guided long tube insertion (LTI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional long tube insertion (LTI)
Number of subjects: 20
Study: 17482925

Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite (CaHA; Coaptite)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Bovine dermal collagen (Contigen)
Number of subjects: 296
Study: 15112907

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg tid in conjunction with a comprehensive behavioral program
Number of subjects: 20
Study: 11231366

Group type: EXPERIMENTAL
Intervention: Daily multivitamin containing 1 mg of folic acid for four weeks
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Vitamin B(12) 1 mg/day for an additional four weeks
Number of subjects: 81

Group type: COMPARATOR
Intervention: High-dose folic acid (0, 5, or 20 mg) for four weeks
Number of subjects: 81
Study: 9704681

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 285
Study: 7527321

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fosphenytoin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stiripentol
Number of subjects: 0
Study: 2656096

Group type: EXPERIMENTAL
Intervention: Cefoxitin (2 g iv for three doses/8 h)
Number of subjects: 1319

Group type: EXPERIMENTAL
Intervention: Penicillin G (2 million U iv for four doses/6 h)
Number of subjects: 1319

Group type: COMPARATOR
Intervention: No antibiotic (control group)
Number of subjects: 1319
Study: 29325594

Group type: EXPERIMENTAL
Intervention: Acupuncture at the sphenopalatine acupoint (SPA) with needle depth 50 mm
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sham acupuncture with needle depth 20 mm
Number of subjects: 61
Study: 26850798

Group type: EXPERIMENTAL
Intervention: Teucrium polium (250 mg q6h for the first 3 days of menstruation for two cycles)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Mefenamic acid (250 mg)
Number of subjects: 70
Study: 25656524

Group type: EXPERIMENTAL
Intervention: 25-hydroxycholecalciferol (3 mg of Hidroferol, 180,000 IU)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (usual treatment for controlling Ca/P levels)
Number of subjects: 94
Study: 23635344

Group type: EXPERIMENTAL
Intervention: Fluid balance charts (intervention group, n = 84)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (n = 86) with access to fluid balance data
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Fluid balance charts (intervention group)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 170
Study: 20045700

Group type: EXPERIMENTAL
Intervention: Linaclotide 75 microg
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Linaclotide 150 microg
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Linaclotide 300 microg
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Linaclotide 600 microg
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 18480689

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/d (2 x 10 mg)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 15837245

Group type: EXPERIMENTAL
Intervention: TAXUS stent
Number of subjects: 1314

Group type: EXPERIMENTAL
Intervention: TAXUS stent (insulin-requiring subgroup)
Number of subjects: 1314
Study: 12534758

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 354

Group type: COMPARATOR
Intervention: Consult-liaison care
Number of subjects: 354
Study: 10937930

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 8522681

Group type: EXPERIMENTAL
Intervention: Cilazapril (angiotensin-converting enzyme inhibitor)
Number of subjects: 1434
Study: 1884962

Group type: EXPERIMENTAL
Intervention: Hourly intravenous injections of 100 mg of cimetidine along with a continuous nasogastric infusion of a liquid antacid at the rate of 0.5 ml per minute
Number of subjects: 0
Study: 6810994

Group type: EXPERIMENTAL
Intervention: Nuclear magnetic resonance imaging
Number of subjects: 22
Study: 31618605

Group type: EXPERIMENTAL
Intervention: Test meal (white bread, almonds)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control meal (white bread, butter, cheese)
Number of subjects: 7
Study: 30705584

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 120
Study: 28288595

Group type: EXPERIMENTAL
Intervention: Mindful Yoga
Number of subjects: 65

Group type: COMPARATOR
Intervention: Social support condition (control)
Number of subjects: 65
Study: 26622078

Group type: EXPERIMENTAL
Intervention: Midazolam (1.0 mg/kg, up to 3 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 32
Study: 23602205

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg elemental Zn/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 22473155

Group type: EXPERIMENTAL
Intervention: Cetuximab and FLOX (arm B)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Cetuximab combined with intermittent FLOX (arm C)
Number of subjects: 571

Group type: COMPARATOR
Intervention: Standard Nordic FLOX (arm A)
Number of subjects: 571
Study: 19480231

Group type: EXPERIMENTAL
Intervention: Exercise training (three 60-minute, supervised, exercise sessions per week for 4 months)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No training (control) for 4 months
Number of subjects: 25